Pharma Likelihood Of Approval
We are the trusted, gold standard intelligence provider to the world’s largest industries
GlobalData powers faster, more informed decisions with:
- Granular industry intelligence: We develop deep, vertical-specific intelligence tailored to your industry, providing 360° insight.​
- Exhaustive coverage: We synthesize our vast data universe into formats that support your decision-making needs, covering the sectors, themes, companies and geographies that matter to you. ​
- Proprietary datasets: We provide you with access to untapped pools of intelligence generated from our proprietary datasets and primary research capabilities. ​
- Robust methodologies: The quality and timeliness of our data is a key differentiator. We leverage robust research methodologies to turn millions of data points into trusted intelligence.
Thousands of companies, government organizations, and decision makers rely on GlobalData
We have a track record of serving truly diverse clients, including:
- Corporates: From helping the C-suite refine strategy to powering innovation in marketing and R&D, our corporate use cases are endless. ​
- Investment firms: We help financial analysts develop robust long-term strategies and get alpha signals before the rest. ​
- Professional services: We give consultants, legal, and accounting firms the critical insights to make faster, more informed decisions. ​
- Other sectors: From media to academia, we work with sectors as diverse as our data. ​
The trusted, actionable and future-proof insight you need to stay ahead
We have decades of experience in being the gold standard intelligence provider based on: ​
- Unique data: Proprietary datasets built from terabytes of data. Our unmatched intelligence gives you true strategic advantage.
- Expert analysis: Leverage collective expertise. Count on our extensive team of researchers, analysts, subject matter experts, and journalists, plus thousands of external thought-leaders.​
- Real intelligence over AI: Experience a level of analysis that leaves AI in the dust. Unlock the proprietary datasets unseen by AI and gain a decisive edge. ​
- Time-saving research solutions: Save hundreds of hours on research. Our comprehensive reports let you focus on delivering actionable insights - not searching for them. ​
- Unparalleled global coverage: Tap into insights from anywhere. Our extensive global coverage offers an unrivalled view of the market landscape.​
- One platform: Access all our unique data, expert analysis, and innovative solutions on one platform. ​
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - LIOCYXM-004 in Hepatocellular Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LIOCYXM-004 in Hepatocellular Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.LIOCYXM-004 in Hepatocellular CarcinomaDrug Details:LioCyxM-004 is under development for the treatment of Hepatitis...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - SHR-1316 in Advanced Malignancy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SHR-1316 in Advanced Malignancy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.SHR-1316 in Advanced MalignancyDrug Details:SHR-1316 is under development for the treatment of advanced...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - IOA-244 in Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IOA-244 in Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.IOA-244 in Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis)Drug Details:IOA-244 is under...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - IOA-244 in Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IOA-244 in Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.IOA-244 in Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic LymphadenopathyDrug Details:IOA-244 is under...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - EVX-02 in Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EVX-02 in Melanoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.EVX-02 in MelanomaDrug Details:EVX-02 is under development for the treatment of resected melanoma. The drug...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - ARB-202 in Metastatic Liver Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ARB-202 in Metastatic Liver Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.ARB-202 in Metastatic Liver CancerDrug Details:ARB-202 is under development for the treatment...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - ARB-202 in Gastrointestinal Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ARB-202 in Gastrointestinal Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.ARB-202 in Gastrointestinal TumorDrug Details:ARB-202 is under development for the treatment of refractory...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - INOA-002 in Zika Virus Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - INOA-002 in Zika Virus Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.INOA-002 in Zika Virus InfectionsDrug Details:INOA-002 is under development for the treatment...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - SH-2442 in Non-Alcoholic Steatohepatitis (NASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SH-2442 in Non-Alcoholic Steatohepatitis (NASH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.SH-2442 in Non-Alcoholic Steatohepatitis (NASH)Drug Details:SH-2442 is under development for the treatment...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - IDE-397 in Thymic Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IDE-397 in Thymic Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IDE-397 in Thymic Carcinoma Drug Details: IDE397 is under development for...